Apollo Endosurgery is a holding company. Through its subsidiaries, Co. is a medical technology company primarily focused on the design, development and commercialization of medical devices to develop gastrointestinal (GI) therapeutic endoscopy. Co.'s products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat various GI conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders (peroral endoscopic myotomy); esophageal stent fixation and obesity. The APEN stock yearly return is shown above.
The yearly return on the APEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the APEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|